Horm Metab Res 1989; 21(9): 514-518
DOI: 10.1055/s-2007-1009274
Clinical

© Georg Thieme Verlag, Stuttgart · New York

Plasma Atrial Natriuretic Peptide, Plasma Renin Activity and Aldosterone during Treatment of Hyperthyroidism due to Graves' Disease

S. Shigematsu1 , T. Iwasaki1 , T. Aizawa1 , M. Ishihara1 , T. Shinoda1 , T. Yamada1 , A. Sato2 , Y. Takemura2
  • 1Department of Gerontology, Endocrinology and Metabolism, School of Medicine, Shinshu University, Matsumoto-shi, Nagano-ken, Japan
  • 2Department of Medicine, Dokkyo Medical College, Koshigaya-shi, Saitama-ken, Japan
Further Information

Publication History

1988

1989

Publication Date:
14 March 2008 (online)

Preview

Summary

Plasma atrial natriuretic peptide (ANP), plasma renin activity (PRA) and aldosterone were consecutively measured during methimazole treatment in patients with hyperthyroidism due to Graves' disease. ANP values of untreated hyperthyroid patients varied greatly from patient to patient, but decreased progressively with a decrease of serum thyroid hormone concentration during methimazole treatment. PRA was elevated in hyperthyroid patients but less aldosterone was secreted as evidenced by lower aldosterone/PRA ratio in these patients than in normal subjects and in hypertensive patients treated with thiazide. In addition, aldosterone/PRA ratio increased progressively with a decrease of ANP during methimazole treatment. The data indicated that ANP secretion was increased and ANP thus secreted depressed aldosterone secretion in hyperthyroid patients. Propranolol depressed pulse rate but failed to affect ANP secretion. It is suggested that thyroid hormone specifically acts on myocytes to stimulate ANP secretion but physiologic significance of such increased ANP secretion remains to be solved.